SAVEME
"A Modular Nanosystems Platform for Advanced Cancer Management: Nano-vehicles; Tumor Targeting and Penetration Agents; Molecular Imaging, Degradome based Therapy"
| Coordinatore | TEL AVIV UNIVERSITY
Organization address
address: RAMAT AVIV contact info |
| Nazionalità Coordinatore | Israel [IL] |
| Sito del progetto | http://fp7-saveme.com/ |
| Totale costo | 13˙809˙085 € |
| EC contributo | 10˙500˙000 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2010-LARGE-4 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-03-01 - 2015-02-28 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TEL AVIV UNIVERSITY
Organization address
address: RAMAT AVIV contact info |
IL (TEL AVIV) | coordinator | 842˙728.00 |
| 2 |
BAR ILAN UNIVERSITY
Organization address
address: BAR ILAN UNIVERSITY CAMPUS contact info |
IL (RAMAT GAN) | participant | 1˙123˙440.00 |
| 3 |
UNIVERSITAETSKLINIKUM HEIDELBERG
Organization address
address: IM NEUENHEIMER FELD 672 contact info |
DE (HEIDELBERG) | participant | 967˙806.00 |
| 4 |
MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER
Organization address
address: TEL HASHOMER SHEBA MEDICAL CENTER contact info |
IL (RAMAT GAN) | participant | 873˙865.00 |
| 5 |
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Organization address
address: ISMANINGER STRASSE 22 contact info |
DE (MUENCHEN) | participant | 630˙670.00 |
| 6 |
WEIZMANN INSTITUTE OF SCIENCE
Organization address
address: HERZL STREET 234 contact info |
IL (REHOVOT) | participant | 601˙107.00 |
| 7 |
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES
Organization address
address: PASEO MIRAMON PARQUE TECNOLOGICO DE SAN SEBASTIAN EDIFICIO EMPRESARIAL C 182 contact info |
ES (SAN SEBASTIAN) | participant | 584˙000.00 |
| 8 |
SHEMYAKIN AND OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY - RUSSIAN ACADEMY OF SCIENCE
Organization address
address: UL. MIKLUKHO MAKLAYA 16/10 contact info |
RU (MOSCOW) | participant | 560˙636.00 |
| 9 |
FUNDACION CIDETEC
Organization address
address: Parque Tecnologico de Miramon, Paseo Miramon 196 contact info |
ES (DONOSTIA - SAN SEBASTIAN) | participant | 553˙020.00 |
| 10 |
UNIVERSITY OF EAST ANGLIA
Organization address
address: EARLHAM ROAD contact info |
UK (NORWICH) | participant | 504˙200.00 |
| 11 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 470˙236.00 |
| 12 |
ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA
Organization address
address: Via Zamboni 33 contact info |
IT (BOLOGNA) | participant | 461˙600.00 |
| 13 |
OSM-DAN LTD.
Organization address
address: Pekeris Street 4 contact info |
IL (REHOVOT) | participant | 381˙640.00 |
| 14 |
nHance Technologies Limited
Organization address
address: 5 BRUTON WAY contact info |
UK (London) | participant | 359˙023.00 |
| 15 |
FILARETE SERVIZI SRL
Organization address
address: VIALE ORTLES 22 4 contact info |
IT (MILANO MI) | participant | 356˙800.00 |
| 16 |
BENCAR AB
Organization address
address: DAG HAMMARKJOLD VAG 52B contact info |
SE (UPPSALA) | participant | 338˙496.00 |
| 17 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | participant | 252˙748.00 |
| 18 |
VEREIN ZUR FOERDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AM WILHELMINENSPITAL DER STADT WIEN
Organization address
address: Montleartstrasse 37 contact info |
AT (WIEN) | participant | 229˙064.00 |
| 19 |
RESEARCH AND PRODUCTION COMPLEX NANOSYSTEM LLC
Organization address
address: 7TH KOZHUKHOVSKAYA 20 contact info |
RU (MOSKVA) | participant | 165˙200.00 |
| 20 |
ASCEND TECHNOLOGIES LIMITED
Organization address
address: TOMKYNS CLOSE 14 contact info |
UK (EASTLEIGH HAMPSHIRE) | participant | 133˙578.00 |
| 21 |
COLOROBBIA ITALIA SPA
Organization address
address: VIA PIETRAMARINA 53 contact info |
IT (SOVIGLIANA VINCI) | participant | 56˙451.00 |
| 22 |
GEMS PET SYSTEMS AB
Organization address
address: HUSBYBORG contact info |
SE (UPPSALA) | participant | 40˙162.00 |
| 23 |
COLOROBBIA CONSULTING SRL
Organization address
address: VIA PIETRAMARINA 53 contact info |
IT (SOVIGLIANA) | participant | 13˙530.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'SaveMe project will address current urgent needs for pancreatic cancer diagnosis and treatment by exploiting partners’ expertise and most recent research achievements for the design and development of novel modular nanosystems platform integrating new functionalized nano-core particles and active agents. The modular platform will enable the design of diverse active nanosystems per diagnostic or therapeutic application as defined by their active agent compositions. For diagnostics, superior tracers will be developed for molecular MR/PET and gamma camera imaging, enabling efficient diagnosis and guided surgery respectively. Novel functionalized nano-core systems will be conjugated with semi-confluent active shell layer. Three types of shell layers will be design: (1) novel iron oxide nanoparticles as advanced MRI contrast agents and/or (2) DOTA complexes for MRI (with Gd3), or PET (with Ga-68), or gamma camera (with Ga-69); (3) Integrating within one tracer both iron oxide nanoparticles and DOTA-Ga-68 complexes for a sequential or simultaneous MR/PET imaging. For therapeutics, active nanosystems will be developed to deliver (1) therapeutic siRNAs or (2) anti-MP-inhibitory-scFVs. These non-classic anti-tumor drugs will be designed based on an extensive tumor degradome analysis for combining blockage of selective matrix MPs, thus preventing basic invasive and metastasis steps, with siRNA based neutralization of secondary molecular effects induced by the specific protease inhibition. Individualized degradome analysis will be developed for potential profiling of anti-MP and siRNAs based therapy per patient. To facilitate the above diagnostics and therapeutic effects, advanced tumor targeting and penetration active agents will be linked to nano-core functionalized groups, including a biocompatible PEG layer linked to tumor selective MMP substrate molecules and highly safe and potent novel somatostatin analogue peptides targeting SSTR overexpression.'